Video

ASH13: The ENESTnd trial update

Publish date: December 8, 2013

 

Updated results from the ENESTnd trial at 5 years showed nilotinib sustained efficacy, compared with imatinib, in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Dr. Giuseppe Saglio puts these 5-year data into perspective.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

BTK inhibitor ibrutinib in CLL and mantle cell lymphoma
MDedge Hematology and Oncology
Sales of leukemia drug suspended because of treatment-associated vascular events
MDedge Hematology and Oncology
Obinutuzumab approved as ‘breakthrough’ therapy for chronic lymphocytic leukemia
MDedge Hematology and Oncology
Oral Chinese formula rivals IV arsenic in acute promyelocytic leukemia
MDedge Hematology and Oncology
CTL019 induced durable responses in children with refractory precursor B-ALL
MDedge Hematology and Oncology
ASH coverage preview of the plenary session
MDedge Hematology and Oncology
Reduced-intensity pre-transplant conditioning found easier on the brain
MDedge Hematology and Oncology
Ethnic differences in stem cell transplants may be narrowing
MDedge Hematology and Oncology
Age barrier falls for half-matched bone marrow transplants
MDedge Hematology and Oncology
Ponatinib sales and marketing suspended
MDedge Hematology and Oncology